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How should we assess the medical signifi-
cance of a virus that infects many persons 
but seems innocuous? Take cytomegalo-
virus (CMV) as an example; most of the 
world’s adults are seropositive without any 
symptoms they can attribute to this infec-
tion; so should we dismiss CMV as an 
unimportant pathogen? Before doing so, we 
should acknowledge that subjective assess-
ments of disease associations reported by 
patients can be misleading. For example, 
persons who smoke cigarettes may appear 
to be well at the time they are interviewed 
and those with primary human immuno-
deficiency virus (HIV) infection are often 
without overt symptoms. In both cases, 
long-term follow-up was required to deter-
mine the full clinical significance of these 
conditions. What has been revealed by the 
equivalent studies for CMV?
Stored samples from the US National 
Health and Nutrition Examination Survey 
(NHANES) cohort III (1988–1994) were 
tested for CMV immunoglobulin (Ig) G 
antibodies, and findings were epidemi-
ologically typical, with 67% of the adult 
population seropositive [1]. Nevertheless, 
linkage to death certification showed that, 
after a median 13.7-year follow-up from 
the initial serologic assessment, the mor-
tality rate was significantly higher in those 
who were CMV seropositive than in those 
who were seronegative. The effect was 
attenuated by controlling for risk factors, 
including diabetes, smoking, and obesity, 
but it remained significant, with a relative 
hazard for death of 1.19 (that is, a 19% rel-
ative increase in mortality). This strikingly 
large effect prompted investigators from 
a second large population cohort in the 
United Kingdom to retrieve their serum 
samples and test for CMV IgG. They 
reported that, after a mean follow-up of 
14.3 years, the 59% of the population who 
were CMV seropositive had a very similar 
relative hazard of 1.16 for death, after con-
trolling for established risk factors [2]. In 
both studies, excess deaths were attributed 
to cardiovascular disease and to cancer 
[1, 2] Is it plausible that this association is 
causal? Are there any known mechanisms 
that might link asymptomatic CMV infec-
tion to an excess of deaths? Is there evi-
dence of a similar association with other 
herpesviruses, or is CMV unique among 
that virus family? Remarkably, there 
several biologic phenomena that might 
explain such an association.
CMV persists lifelong by hiding from 
the immune system [3]. It does this by 
expressing its immune evasion genes so 
that infected cells remain invisible to the 
immune system, allowing CMV to per-
sist in sanctuary sites within the body [4, 
5]. Some immune evasion genes provide 
decoy signals to natural killer (NK) cells 
and macrophages equivalent to those on 
healthy host cells, while others interfere 
with the stress signals that would oth-
erwise stimulate an NK attack on cells 
whose biochemistry has been hijacked 
by a virus [4]. Many of these signals work 
through the HLA class I system, either by 
interfering with normal display of these 
proteins at the cell surface or by increas-
ing display of inhibitory molecules, such 
as HLA-E [6]. The net effect is that the 
number of T cells that become com-
mitted to searching for CMV sanctuary 
sites increases as we age and acquire the 
TEMRA phenotype (T-effector cells reex-
pressing the RA marker classically associ-
ated with naive rather than memory cells) 
[7–9]. Likewise, the surface proteins 
expressed by NK cells become changed to 
express phenotypic markers that can be 
detected readily [10–12]. 
It is not clear whether all these changes 
are driven by a small number of sanctuary 
sites established during primary infection 
or whether periodic reactivations of latent 
virus or reinfections with different strains 
of CMV are also required. Nevertheless, 
after years or decades of clinically silent 
CMV infection, the immune system com-
mits more resources to CMV than to all 
the other viruses an elderly person has 
encountered in his or her life [13]. This 
has 3 major potential effects: the excess of 
immune cells could contribute to chronic 
inflammatory diseases such as athero-
sclerosis; the relative lack of naive T cells 
could impair the ability of elderly persons 
to respond to new antigens of pathogens, 
including those found in vaccines; and the 
normal immune surveillance function of 
these cells could be impaired. Death would 
be attributed to atherosclerosis in the first 
scenario, to influenza or pneumococcal 
disease in the second scenario and to can-
cer in the third scenario, without recogniz-
ing the contribution made by underlying 
CMV infection. Put bluntly, physicians 
caring for elderly persons may currently 
be writing incomplete death certificates 
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that provide the overt, distal cause of death 
without recording the covert, proximal 
long-term contribution made by CMV.
In this issue of The Journal of Infectious 
Diseases, Dowd et  al [14] discuss yet 
another potential mechanism. In a longi-
tudinal study design involving 3-year fol-
low-up in 400 healthy, middle-aged civil 
servants, the change in telomere length of 
peripheral blood mononuclear cells was 
described and related to the presence at 
baseline of IgG antibodies against 4 her-
pesviruses. Three of these (CMV, herpes 
simplex virus, human herpesvirus 6) were 
associated with attrition of telomere 
lengths. The strongest effect came from 
CMV, with evidence of an additive effect 
from multiple herpesviruses. The effect 
size was large, equivalent to 12 chron-
ological years of normal aging in those 
who were CMV seropositive. The effect of 
shortened telomeres will be familiar to lab-
oratory researchers in terms of the number 
of cell divisions that are possible in vitro 
before cells become senescent (Hayflick 
limit) [15]. It is tempting to speculate that 
an equivalent process in vivo would lead to 
progressive dysfunction of cells in organs 
and in the immune system, thereby con-
tributing to immunosenescence. Although 
comparison of telomere lengths from cells 
of individuals of different ages does not 
support that simple conclusion, telomere 
shortening is, nevertheless, taken to repre-
sent a general process of aging within an 
individual [16, 17].
Thus, we have multiple plausible mech-
anisms linking CMV, and perhaps other 
herpesviruses, with causes of death. It 
should be noted that the various phenom-
ena studied so far overlap. For example 
TEMRA T cells have shortened telomeres, 
chronic stress or inflammation can 
shorten telomeres, and stress is known 
to trigger reactivation of herpesviruses, 
as illustrated dramatically by studies of 
astronauts [9, 17–19]. Assuming that 
some of these effects turn out to be truly 
caused by CMV and other herpesviruses, 
what action could be taken? Universal 
immunization with a vaccine able to pro-
tect individuals against primary infection 
would be effective, but only after many 
decades [20]. As probes of pathogenesis, 
vaccines are specific for each virus and 
could be used for immunotherapy to 
determine if boosting of immunity con-
trols each virus and its putative effects on 
immunosenescence. Immunotherapy for 
herpesviruses has been reported for vari-
cella-zoster virus and CMV [21–23]. 
In contrast, antiviral drugs give a more 
immediate inhibition of virus replication, 
and may have pan-herpesvirus activ-
ity. Clinical trials of these drugs should, 
therefore, investigate effects on all herpes-
viruses, not just on the one being targeted. 
A course of chemotherapy could be given 
as part of an investigational randomized 
controlled trial. It would be unrealistic 
to ask grant-giving bodies to support the 
long-term follow-up required to exam-
ine survival as an end point, but rever-
sal of abnormal immunologic indices 
attributed to CMV or reversal of telomere 
attrition would represent good first steps. 
Accordingly, the abundance of activated 
CD8 T cells was significantly reduced in 
a double-blind, randomized placebo-con-
trolled trial of valganciclovir in HIV-
positive patients [24]. To expand on the 
findings reported by Dowd et  al [24] in 
this issue, the enzyme telomerase could 
be activated to increase telomere lengths, 
but caution is required, because this enzy-
matic activity is associated with the unde-
sirable life extension found in cancer cells.
The challenge now is for investigators to 
determine whether the various reported 
associations with herpesviruses are causal 
and whether their effects can be amelio-
rated through the repurposing of existing 
medical interventions. The prize is none 
other than the potential slowing down of 
the aging process that has been taken to 
be part of normal life, but might be reclas-
sified as having a pathologic component 
driven by silent herpesvirus infections.
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